Dysregulation of the annexin family protein family is associated with prostate cancer progression

American Journal of Pathology

Volumn 162, Issue 1, 2003, Pages 255-261

  Xin, Wei ^a   Rhodes, Daniel R ^a   Ingold, Collette ^a   Chinnaiyan, Arul M ^a   Rubin, Mark A ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANNEXIN; ISOPROTEIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FAMILY; TISSUE LEVEL;

EID: 0037221729     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)63816-3     Document Type: Article

References (36)

1. Ruijter E, van de Kaa C, Miller G, Ruiter D, Debruyne F, Schalken J: Molecular genetics and epidemiology of prostate carcinoma. Endocr Rev 1999, 20:22-45
2. Abate-Shen C, Shen MM: Molecular genetics of PCa. Genes Dev 2000, 14:2410-2434
3. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Fianigan RC, deKernion JB, Ratliff TL, Kavouss LR, Dalkin BL, et al.: Comparison of digital rectal examination and serum prostate specific antigen in the early detection of PCa: Results of a multicenter clinical trial of 6,630 men. J Urol 1994, 151:1283-1290
4. Etzioni R, Legler JM, Feuer EJ, Merrill RM, Cronin KA, Hankey BF: Cancer surveillance series: Interpreting trends in PCa - Part III: Quantifying the link between population prostate-specific antigen testing and recent declines in PCa mortality. J Natl Cancer Inst 1999, 91:1033-1039
5. Liotta L, Petricoin E: Molecular profiling of human cancer. Nat Rev Genet 2000, 1:48-56
6. Welsh JB, Sapinoso LM, Su AI, Kern SG, Wang-Rodriguez J, Moskaluk CA, Frierson Jr HF, Hampton GM: Analysis of gene expression identifies candidate markers and pharmacological targets in PCa. Cancer Res 2001, 61:5974-5978
7. Luo J, Duggan DJ, Chen Y, Sauvageot J, Ewing CM, Bittner ML, Trent JM, Isaacs WB: Human PCa and benign prostatic hyperplasia: Molecular dissection by gene expression profiling. Cancer Res 2001, 61:4683-4688
8. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM: Delineation of prognostic biomarkers in PCa. Nature 2001, 412:822-826
9. Magee JA, Araki T, Patil S, Ehrig T, True L, Humphrey PA, Catalona WJ, Watson MA, Milbrandt J: Expression profiling reveals hepsin overexpression in PCa. Cancer Res 2001, 61:5692-5696
10. Smith PD, Moss SE: Structural evolution of the annexin supergene family. Trends Genet 1994, 10:241-246
11. Mailliard WS, Haigler HT, Schlaepfer DD: Calcium-dependent binding of S100C to the N-terminal domain of annexin I. J Biol Chem 1996, 271:719-725
12. Waisman DM: Annexin II tetramer: Structure and function. Mol Cell Biochem 1995, 149-150:301-322
13. Paweletz CP, Ornstein DK, Roth MJ, Bichsel VE, Gillespie JW, Calvert VS, Vocke CD, Hewitt SM, Duray PH, Herring J, Wang QH, Hu N, Linehan WM, Taylor PR, Liotta LA, Emmert-Buck MR, Petricoin III EF: Loss of annexin 1 correlates with early onset of tumorigenesis in esophageal and prostate carcinoma. Cancer Res 2000, 60:6293-6297
14. Srivastava M, Bubendorf L, Srikantan V, Fossom L, Nolan L, Glasman M, Leighton X, Fehrle W, Pittaluga S, Raffeld M, Koivisto P, Willi N, Gasser TC, Kononen J, Sauter G, Kallioniemi OP, Srivastava S, Pollard HB: ANX7, a candidate tumor suppressor gene for PCa. Proc Natl Acad Sci USA 2001, 98:4575-4580
15. Hollenbeck BK, Bassily N, Wei JT, Montie JE, Hayasaka S, Taylor JM, Rubin MA: Whole mounted radical prostatectomy specimens do not increase detection of adverse pathological features. J Urol 2000, 164:1583-1586
16. Rubin MA, Putzi M, Mucci N, Smith DC, Wojno K, Korenchuk S, Pienta KJ: Rapid ("warm") autopsy study for procurement of metastatic PCa. Clin Cancer Res 2000, 6:1038-1045
17. Bostwick DG, Foster CS: Predictive factors in PCa: Current concepts from the 1999 College of American Pathologists Conference on Solid Tumor Prognostic Factors and the 1999 World Health Organization Second International Consultation on Prostate Cancer. Semin Urol Oncol 1999, 17:222-272
18. Gleason DF: Classification of prostatic carcinomas. Cancer Chemother Rep 1966, 50:125-128
19. Tannenbaum MP: Urologic Pathology: The Prostate. Philadelphia, Lea and Febiger, 1977, pp xii and 419
20. Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, Sanda MG, Pienta KJ, Ghosh D, Chinnaiyan AM: Apha-methylacyl coenzyme A racemase as a tissue biomarker for PCa. JAMA 2002, 287:1662-1670
21. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998, 4:844-847
22. Perrone EE, Theoharis C, Mucci NR, Hayasaka S, Taylor JM, Cooney KA, Rubin MA: Tissue microarray assessment of PCa tumor proliferation in African-American and white men. J Natl Cancer Inst 2000, 92:937-939
23. Hedges LV, Olkin I: Statistical Methods for Meta-Analysis. Orlando, Academic Press, 1985, pp xxii and 369
24. Scheffé H: The Analysis of Variance. New York, Wiley, 1959, p 477
25. Rhodes DR, Barrette TR, Rubin MA, Ghosh D, Chinnaiyan AM: Meta-analysis of microarrays: Interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res 2002, 62:4427-4433
26. Chang KS, Wang G, Freireich EJ, Daly M, Naylor SL, Trujillo JM, Stass SA: Specific expression of the annexin VIII gene in acute promyelocytic leukemia. Blood 1992, 79:1802-1810
27. Cole SP, Pinkoski MJ, Bhardwaj G, Deeley RG: Elevated expression of annexin II (lipocortin II, p36) in a multidrug resistant small cell lung cancer cell line. Br J Cancer 1992, 65:498-502
28. Vishwanatha JK, Chiang Y, Kumble KD, Hollingsworth MA, Pour PM: Enhanced expression of annexin II in human pancreatic carcinoma cells and primary pancreatic cancers. Carcinogenesis 1993, 14: 2575-2579
29. Roseman BJ, Bollen A, Hsu J, Lamborn K, Israel MA: Annexin II marks astrocytic brain tumors of high histologic grade. Oncol Res 1994, 6:561-567
30. Theobald J, Hanby A, Patel K, Moss SE: Annexin VI has tumour-suppressor activity in human A431 squamous epithelial carcinoma cells. Br J Cancer 1995, 71:786-788
31. Xia SH, Hu LP, Hu H, Ying WT, Xu X, Cai Y, Han YL, Chen BS, Wei F, Qian XH, Cai YY, Shen Y, Wu M, Wang MR: Three isoforms of annexin I are preferentially expressed in normal esophageal epithelia but down-regulated in esophageal squamous cell carcinomas. Oncogene 2002, 21:6641-6648
32. Pepinsky RB, Sinclair LK: Epidermal growth factor-dependent phosphorylation of lipocortin. Nature 1986, 321:81-84
33. Wallner BP, Mattaliano RJ, Hession C, Cate RL, Tizard R, Sinclair LK, Foeller C, Chow EP, Browing JL, Ramachandran KL, et al. Cloning and expression of human lipocortin, a phospholipase A2 inhibitor with potential anti-inflammatory activity. Nature 1986, 320:77-81
34. Hubaishy I, Jones PG, Bjorge J, Bellagamba C, Fitzpatrick S, Fujita DJ, Waisman DM: Modulation of annexin II tetramer by tyrosine phosphorylation. Biochemistry 1995, 34:14527-14534
35. Chan HC, Kaetzel MA, Gotter AL, Dedman JR, Nelson DJ: Annexin IV inhibits calmodulin-dependent protein kinase II-activated chloride conductance. A novel mechanism for ion channel regulation. J Biol Chem 1994, 269:32464-32468
36. Selbert S, Fischer P, Menke A, Jockusch H, Pongratz D, Noegel AA: Annexin VII relocalization as a result of dystrophin deficiency. Exp Cell Res 1996, 222:199-208